Abstract:Key PointsCell-free DNA (cfDNA) is released predominantly by cell death into the bloodstream, although active secretion may have a role. Since the discovery of fetal cfDNA in the maternal circulation, cfDNA analysis has been rapidly implemented in clinical practice for noninvasive prenatal testing.Mutations were first detected in cfDNA more than two decades ago, and interest in circulating tumour DNA (ctDNA) as a noninvasive cancer diagnostic has increased considerably with the development of molecular methods that permit the sensitive detection and monitoring of multiple classes of mutation.ctDNA may have utility at almost every stage of the management of patients with cancer, including diagnosis, minimally invasive molecular profiling, treatment monitoring, the detection of residual disease and the identification of resistance mutations. ctDNA analysis may be broadly considered as a tool both for quantitative analysis of disease burden and for genomic analysis.The identification of ctDNA in individuals before a cancer diagnosis, and in presymptomatic individuals, suggests the possibility of ctDNA analysis as a tool for earlier detection and screening. Noninvasive cancer classification or subtyping has also emerged as a possibility, although for early detection, both technical and biological factors introduce challenges to the detection of mutant DNA in plasma and its interpretation.Monitoring multiple mutations in parallel can enhance the sensitivity of ctDNA detection, can be used to assess the clonal evolution of patients' disease and may identify resistance mutations before clinical progression is observed.ctDNA analysis is beginning to transition from the research setting into the clinic. The US Food and Drug Administration and the European Medicines Agency have approved ctDNA tests for specific indications in the absence of evaluable tumour tissue. Analysis of gene panels in plasma has now become available as a potential clinical tool. Large studies are under way to establish the overall performance and clinical utility of such assays when a tumour biopsy is not available for analysis.Potential applications of ctDNA have been demonstrated by a number of proof-of-principle studies. Prospective clinical trials are beginning to assess the clinical utility of ctDNA analysis for molecular profiling and disease monitoring. The increasing acceptance of ctDNA is enabling the field to move from exploratory ctDNA studies towards clinical trials in which ctDNA guides decision-making.In order to fully exploit the potential utility of liquid biopsies, it is essential that the biology of cfDNA and ctDNA is explored further. The mechanisms of release and degradation, and the factors that affect the representation of ctDNA in plasma, are poorly understood. The nature of ctDNA will be clarified through both large, well-annotated clinical studies and in vivo studies in which variables can be controlled.

The main sources of circulating cell-free DNA: Apoptosis, necrosis and active secretion

Challenges and Prospects of Cell-Free DNA in Precision Oncology

Cell-Free DNA Fragmentomics: the Novel Promising Biomarker

Life and death of circulating cell-free DNA

Cell-Free DNA: Hope and Potential Application in Cancer

Cell‐free DNA‐associated Multi‐feature Applications in Cancer Diagnosis and Treatment

Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy

The functional and clinical roles of liquid biopsy in patient-derived models

Liquid biopsies come of age: towards implementation of circulating tumour DNA

The emerging role of cell-free DNA as a molecular marker for cancer management

Liquid Biopsies: DNA Methylation Analyses in Circulating Cell-Free DNA

Cell-free Circulating Tumor DNA in Cancer

Characterization of the Release and Biological Significance of Cell-Free DNA from Breast Cancer Cell Lines.

The Interplay of Circulating Tumor DNA and Chromatin Modification, Therapeutic Resistance, and Metastasis.

Cell-Free Dna in the Circulation As A Potential Cancer Biomarker

Circulating Cell-Free DNA for Cancer Early Detection

Cell-free DNA end characteristics enable accurate and sensitive cancer diagnosis

Circulating tumor DNA in liquid biopsy: Current diagnostic limitation

Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals

Circulating cell-free DNA fragmentation is a stepwise and conserved process linked to apoptosis

Liquid biopsy: unlocking the potentials of cell-free DNA